L3VLUP
ProSign in

VKTX · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

VKTXVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • VKTX
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterVKTXVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 20201 holders, $112k30 holders, $18.4bn
Q1 20211 holders, $245k31 holders, $15.4bn
Q2 20212 holders, $1.0m30 holders, $12.7bn
Q3 20212 holders, $769k35 holders, $10.1bn
Q4 20211 holders, $627k28 holders, $12.4bn
Q1 20221 holders, $290k23 holders, $16.1bn
Q2 20221 holders, $849k25 holders, $18.1bn
Q3 20222 holders, $3.5m22 holders, $18.4bn
Q4 20223 holders, $13m28 holders, $18.4bn
Q1 20234 holders, $71m26 holders, $21.4bn
Q2 20231 holders, $57m27 holders, $24.7bn
Q3 20233 holders, $54m33 holders, $24.3bn
Q4 20232 holders, $138m32 holders, $28.6bn
Q1 20247 holders, $1.6bn31 holders, $29.8bn
Q2 20245 holders, $961m29 holders, $33.4bn
Q3 20245 holders, $1.1bn27 holders, $33.5bn
Q4 20246 holders, $794m26 holders, $28.5bn
Q1 20254 holders, $61m21 holders, $35.4bn
Q2 20253 holders, $72m21 holders, $32.3bn
Q3 20256 holders, $117m22 holders, $25.9bn
Q4 20256 holders, $202m26 holders, $31.8bn
Q1 20262 holders, $156m25 holders, $31.8bn
Q2 20264 holders, $183m26 holders, $34.6bn
VKTX

Viking Therapeutics Inc

Holders
6
Reported value
$202m
Buyers
18
Sellers
9

Breadth +9 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$31.8bn
Buyers
19
Sellers
20

Breadth -1 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only VKTX (4)

Brevan Howard Capital Management LP, ExodusPoint Capital Management LP, Soros Fund Management LLC, Two Sigma Investments LP

Only VRTX (24)

Acadian Asset Management LLC, AllianceBernstein LP, ARK Investment Management LLC, Arrowstreet Capital LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →